Panel Discussion | Devices in Heart Failure

Sunday, March 8, 2026

11:14 AM - 11:34 AM EST

Location: Georgetown

Moderator(s)

William T. Abraham, MD

Professor of Medicine
The Ohio State University
Columbus, Ohio, United States

Disclosure(s): Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); AquaPass: Consulting Fees (e.g., advisory boards) (Ongoing); Bioventrix: Consulting Fees (e.g., advisory boards) (Ongoing); Cardiac Dimensions: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Cordio Medical: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Impulse Dynamics: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Innoventric: Consulting Fees (e.g., advisory boards) (Ongoing); JNJ V-Wave: Consulting Fees (e.g., advisory boards) (Ongoing); SCPharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, October 31, 2025), Stock-publicly held company (excluding mutual/index funds) (Terminated, October 31, 2025); Sensible Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medtech: Consulting Fees (e.g., advisory boards) (Ongoing); WhiteSwell: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll Respicardia: Consulting Fees (e.g., advisory boards) (Ongoing)
Cynthia Bither, NP

NP, Advanced Heart Failure Program
MedStar Washington Hospital Center
Shady Side, Maryland, United States

Disclosure information not submitted.
Navin K. Kapur, MD, FSCAI FAHA FACC

Professor of Medicine
Tufts Medical Center
Boston, Massachusetts, United States

Disclosure information not submitted.

Panel Discussant(s)

Daniel Burkhoff, MD, PhD

Director: Heart Failure, Hemodynamics and MCS Research
Cardiovascular Research Foundation
New York, New York, United States

Disclosure information not submitted.
Marat Fudim, MD

Associate Professor
Duke

Disclosure information not submitted.
Zvonimir Krajcer, MD

PVD program director, Editor-in Chief-THI Journal
Texas Heart Center for Cardiovascular Care at Texas Heart Institute
Houston, Texas, United States

Disclosure(s): Anaxiom Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Second Heart Assist, Inc.: Stock-privately held company (Ongoing); Taurus Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
JoAnn Lindenfeld, MD

Director, Heart Failure and Transplantation
Vanderbilt University
Nashville, Tennessee, United States

Disclosure information not submitted.
Stanton J. Rowe, PhD

CEO
Nidus Biomedical
Irvine, California, United States

Disclosure(s): No financial relationships to disclose
James Udelson, MD

Chief, Division of Cardiology
Tufts Medical Center
Boston, Massachusetts, United States

Disclosure(s): Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Sandip Zalawadiya, MD

Associated Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee, United States

Disclosure(s): Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medical: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):

William T. Abraham, MD: Abbott: Consulting Fees (e.g., advisory boards) (Ongoing); AquaPass: Consulting Fees (e.g., advisory boards) (Ongoing); Bioventrix: Consulting Fees (e.g., advisory boards) (Ongoing); Cardiac Dimensions: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Cordio Medical: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Impulse Dynamics: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Innoventric: Consulting Fees (e.g., advisory boards) (Ongoing); JNJ V-Wave: Consulting Fees (e.g., advisory boards) (Ongoing); SCPharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, October 31, 2025), Stock-publicly held company (excluding mutual/index funds) (Terminated, October 31, 2025); Sensible Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medtech: Consulting Fees (e.g., advisory boards) (Ongoing); WhiteSwell: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll Respicardia: Consulting Fees (e.g., advisory boards) (Ongoing)

Zvonimir Krajcer, MD: Anaxiom Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Second Heart Assist, Inc.: Stock-privately held company (Ongoing); Taurus Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Stanton J. Rowe, PhD: No financial relationships to disclose

James Udelson, MD: Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Sandip Zalawadiya, MD: Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medical: Consulting Fees (e.g., advisory boards) (Ongoing)